SPARK Impact is a multi-fund manager located in the UK and authorised and regulated by the Financial Conduct Authority. The firm is authorised to undertake portfolio fund management as well as being authorised as a Small authorised Sub Threshold Alternative Investment fund manager.

SPARK invests in companies and opportunities through all stage of their development from early stage to growth to providing capital for expansion. It benefits from a team that is able to cover all business sectors with experience in equity, venture debt and mezzanine finance.  Spark offers help to create world class businesses and the best investment opportunities with experience in public, private and public/private funds.

Our role is to identify suitable investment opportunities, conduct due diligence, negotiate, structure investment transactions, and monitor and manage investments until exit.


The North West Fund for Biomedical

The North West Fund for Biomedical is a £30m fund designed to provide flexible equity package(s) for high growth businesses operating within the biomedical sector, these include:

  • pharmaceuticals (research, development and manufacture of drugs and biopharmaceuticals);
  • biotechnology;
  • diagnostics;
  • clinical research organisations;
  • contract manufacturing organisations;
  • analytical services and sciences
  • healthcare technologies, medical devices and implantable's.

SPARK Impact manages the North West Fund for Biomedical, providing finance from £50,000 to £1.5m to businesses to support a broad range of needs from start-up and early stage development through to expansion plans for trading businesses.

The original £25m fund was increased to £30.6m resulting in further follow on investment in 23 existing investee companies. The fund is now fully invested as of December 2015.


SPARK manages >_fund:tmt, which offers funding solutions of between £0.5m and £2m in the technology, media and telecommunications sector. >_fund:tmt is a flexible fund that seeks to invest in established owner-managed TMT companies with annual revenues greater than £1m (of which a significant proportion is recurring) and which have a clear exit route. Find out more at